C116P: Romiplostim Biosimilar, Human TPO Fusion Protein

Catalog No.: C116P | **Product Name:** Romiplostim Biosimilar, Human TPO Fusion Protein

The research grade Romiplostim biosimilar protein is for research use only (RUO). Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C116P
Product Name	Romiplostim Biosimilar, Human TPO Fusion Protein
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	TPO; thrombopoietin protein; MGDF
Summary	Recombinant Thrombopoietin Receptor Agonist Peptibody (Fc-Peptide Fusion Protein).
Construct	Human IgG1 Fc fused to thrombopoietin (TPO) mimetic peptides.
Source/Host	The anti-human TPO fusion protein romiplostim biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade romiplostim biosimilar specifically binds to the TPO protein / thrombopoietin receptor (c-Mpl).
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by romiplostim.
Form Of Protein	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Romiplostim Biosimilar, Human TPO Fusion Protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Romiplostim biosimilar protein is for research use only (RUO). Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is romiplostim biosimilar research grade? Romiplostim (trade name Nplate) is a thrombopoietin receptor agonist (TPO-RA) peptibody consisting of a human IgG1 Fc domain linked to thrombopoietin mimetic peptides. It binds to and activates the thrombopoietin receptor (c-Mpl) on megakaryocytes, stimulating platelet production. Romiplostim is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy, and for the treatment of hematopoietic syndrome of acute radiation syndrome. Romiplostim biosimilar uses the same protein sequences as the therapeutic fusion protein romiplostim.